Evidence map›Paper›PMID 26862218›Full record

ReviewBiochemical Society transactions2016

Phosphoinositide signalling in type 2 diabetes: a β-cell perspective.

Lucia E Rameh, Jude T Deeney

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical Society transactions, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Extrachromosomal Circular DNA and Transposable Elements in Type 2 Diabetes.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lucia E RamehDepartment of Medicine, Boston University School of Medicine, 650 Albany Street, Boston, MA 02118, U.S.A. rameh@bu.edu.
Jude T DeeneyDepartment of Medicine, Boston University School of Medicine, 650 Albany Street, Boston, MA 02118, U.S.A.
Boston University · US

Funding

METABOLIC REGULATION OF INSULIN SECRETIONR01DK035914 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI CORKEY, BARBARA E., SHIRIHAI, ORIAN S · 1986 to 2013
$5.3M
The Role of PtdIns-5-P in Cell Function and SignalingR01DK063219 · NIDDK · BOSTON MEDICAL CENTER · PI RAMEH-PLANT, LUCIA · 2003 to 2012
$4.0M
NIDDK NIH HHS R01 DK035914NIDDK NIH HHS R01 DK 063219NIDDK NIH HHS R01 DK063219NIDDK NIH HHS R01 DK35914
6 · The paper itself

Abstract

Type 2 diabetes is a complex disease. It results from a failure of the body to maintain energy homoeostasis. Multicellular organisms have evolved complex strategies to preserve a relatively stable internal nutrient environment, despite fluctuations in external nutrient availability. This complex strategy involves the co-ordinated responses of multiple organs to promote storage or mobilization of energy sources according to the availability of nutrients and cellular bioenergetics needs. The endocrine pancreas plays a central role in these processes by secreting insulin and glucagon. When this co-ordinated effort fails, hyperglycaemia and hyperlipidaemia develops, characterizing a state of metabolic imbalance and ultimately overt diabetes. Although diabetes is most likely a collection of diseases, scientists are starting to identify genetic components and environmental triggers. Genome-wide association studies revealed that by and large, gene variants associated with type 2 diabetes are implicated in pancreatic β-cell function, suggesting that the β-cell may be the weakest link in the chain of events that results in diabetes. Thus, it is critical to understand how environmental cues affect the β-cell. Phosphoinositides are important 'decoders' of environmental cues. As such, these lipids have been implicated in cellular responses to a wide range of growth factors, hormones, stress agents, nutrients and metabolites. Here we will review some of the well-established and potential new roles for phosphoinositides in β-cell function/dysfunction and discuss how our knowledge of phosphoinositide signalling could aid in the identification of potential strategies for treating or preventing type 2 diabetes.

Indexed as

Signal Transduction1-Phosphatidylinositol 4-KinaseAnimalsDiabetes Mellitus, Type 2HumansInsulinInsulin-Secreting CellsInsulin SecretionPhosphatidylinositols1-Phosphatidylinositol 4-KinaseInsulinPhosphatidylinositolsinsulinlipid kinasesnutrientsobesitysignallingβ-cell

Identifiers

PMID26862218
PMCPMC10760496
OpenAlexW2284968266

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.